Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in second-line small cell lung cancer
NCT03059667Phase 2Completed
- Sponsor
- IFCT
- Start
- Mar 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in small cell lung cancer (SCLC), sponsored by IFCT. Started Mar 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03059667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059667.